A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on higher-reward opportunities elsewhere.
Finding the right balance between safety and returns isn’t easy, which is why StockStory is here to help. That said, here are two low-volatility stocks that could succeed under all market conditions and one stuck in limbo.
One Stock to Sell:
Sysco (SYY)
Rolling One-Year Beta: -0.09
Powering more than 730,000 commercial kitchens across North America and Europe, Sysco (NYSE:SYY) is a global food distributor that supplies restaurants, healthcare facilities, schools, hotels, and other foodservice establishments with food products and related services.
Why Is SYY Risky?
- Unit sales averaged 0.9% growth over the past two years and imply healthy demand for its products
- Free cash flow margin is not anticipated to grow over the next year
- Waning returns on capital from an already weak starting point displays the inefficacy of management’s past and current investment decisions
Sysco’s stock price of $78.29 implies a valuation ratio of 15.5x forward P/E. If you’re considering SYY for your portfolio, see our FREE research report to learn more.
Two Stocks to Watch:
Dutch Bros (BROS)
Rolling One-Year Beta: 0.53
Started in 1992 by two brothers as a single pushcart, Dutch Bros (NYSE:BROS) is a dynamic coffee chain that’s captured the hearts of coffee enthusiasts across the United States.
Why Are We Positive on BROS?
- Aggressive strategy of rolling out new restaurants to gobble up whitespace is prudent given its same-store sales growth
- Average same-store sales growth of 6% over the past two years indicates its restaurants are resonating with diners
- Revenue outlook for the upcoming 12 months is outstanding and shows it’s on track to gain market share
Dutch Bros is trading at $38.70 per share, or 32.5x forward P/E. Is now the time to initiate a position? Find out in our full research report, it’s free.
Insulet (PODD)
Rolling One-Year Beta: -0.56
Revolutionizing diabetes care with its tubeless "Pod" technology, Insulet (NASDAQ:PODD) develops and manufactures innovative insulin delivery systems for people with diabetes, primarily through its Omnipod product line.
Why Should You Buy PODD?
- Constant currency growth averaged 26.7% over the past two years, showing it can expand globally regardless of the macroeconomic environment
- Free cash flow margin jumped by 19.9 percentage points over the last five years, giving the company more resources to pursue growth initiatives, repurchase shares, or pay dividends
- Improving returns on capital reflect management’s ability to monetize investments
At $131.74 per share, Insulet trades at 19.2x forward P/E. Is now the right time to buy? See for yourself in our full research report, it’s free.
Stocks We Like Even More
ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren’t just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum — both boxes checked at the same time.
Find out which stocks our AI platform is flagging this week. See this week’s Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+1,154% between June 2020 and June 2025). Find your next big winner with StockStory today.